Daphne Karydas Net Worth

Daphne Karydas biography

Daphne Karydas has been appointed as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer of the Company effective 7/13/2020. Ms. Karydas joined Allergan in 2017 as Senior Vice President of Global Investor Relations and Strategy, leading engagement with the investment community and business strategy development. Prior to joining Allergan, she served as Executive Director and Senior Healthcare Analyst at J.P. Morgan Asset Management. Previously, she was a Portfolio Manager and Senior Healthcare Analyst at The Boston Company Asset Management, a BNY Mellon company. Earlier, Ms. Karydas was a Vice President at Goldman Sachs Asset Management focused on healthcare, as well as a member of Goldman Sachs' healthcare investment banking team. Before joining Goldman Sachs, she was a Project Chemical Engineer at Merck & Co. where she focused on process development for novel vaccines. Ms. Karydas received a B.A. and M.S. in chemical engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School .

What's Daphne Karydas's mailing address?

Daphne's mailing address filed with the SEC is C/O COMPASS PATHWAYS PLC, 33 BROADWICK STREET, LONDON, X0, W1F 0DQ.

Insiders trading at Syndax Pharmaceuticals Inc

Over the last 9 years, insiders at Syndax Pharmaceuticals Inc have traded over $1,950,406 worth of Syndax Pharmaceuticals Inc stock and bought 210,921 units worth $2,347,816 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Luke Evnin, eBriggs Morrison. On average, Syndax Pharmaceuticals Inc executives and independent directors trade stock every 50 days with the average trade being worth of $745,679. The most recent stock trade was executed by Keith A. Goldan on 14 June 2024, trading 1,250 units of SNDX stock currently worth $25,038.

What does Syndax Pharmaceuticals Inc do?

syndax pharmaceuticals is a biotechnology company located at 35 gatehouse dr., building d, floor 3, waltham, ma 02451.

Syndax Pharmaceuticals Inc executives and stock owners

Syndax Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Michael Metzger,
  President, Chief Operating Officer, Director
• Briggs Morrison,
  Chief Executive Officer, Director
• Dr. Briggs W. Morrison M.D.,
  CEO & Director
• Michael A. Metzger M.B.A.,
  Pres, COO & Director
• Michael Meyers,
  Senior Vice President, Chief Medical Officer
• Dennis Podlesak,
  Independent Chairman of the Board
• Pierre Legault,
  Independent Director
• Keith Katkin,
  Independent Director
• William Meury,
  Independent Director
• Fabrice Egros,
  Independent Director
• Jennifer Jarrett,
  Independent Director
• Peter Ordentlich,
  Chief Scientific Officer
• Luke Albrecht,
  Senior Vice President, General Counsel, Secretary
• Daphne Karydas,
  Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer
• Dr. Edward A. Sausville M.D., Ph.D.,
  Advisor
• Dr. Michael L. Meyers M.D., Ph.D.,
  Chief Medical Officer & Sr. VP
• Luke J. Albrecht,
  Sr. VP, Gen. Counsel & Sec.
• Alexander Nolte,
  Interim Principal Financial Officer, VP & Chief Accounting Officer
• Dr. Michael Downes Ph.D.,
  Co-Founder
• Dr. Ronald M. Evans Ph.D.,
  Co-Founder, Advisor and Chair of Scientific Advisory Board
• Dr. Richard A. Heyman Ph.D.,
  Co-Founder
• Dr. Peter Ordentlich B.Sc., Ph.D.,
  Co-Founder & Chief Scientific Officer
• Martin H. Jr. Huber,
  
• Neil Gallagher,
  President, Head of R&D
• Luke Evnin,
  Director
• Henry Chen,
  
• Partners L P/Ilbiotechnolog...,
  
• Steve M Sabus,
  Chief Commercial Officer
• Ivor Royston,
  Director
• Viii Associates, L.P.Blair ...,
  
• Vi Associates, L.P.Blair Ja...,
  
• Partners Vi, L.P.Blair Jame...,
  
• George W. Jr. Sledge,
  
• Bio Ventures Iv Qp Lp Scopa...,
  
• Partners Viii, L.P.Blair Ja...,
  
• Kim P. Kamdar,
  Director
• Richard P Shea,
  Chief Financial Officer
• Alexander Nolte,
  Chief Accounting Officer
• Catherine Madigan,
  Chief Medical Officer
• Keith A. Goldan,
  Chief Financial Officer